Oruka Therapeutics, Inc.

Clinical trials sponsored by Oruka Therapeutics, Inc., explained in plain language.

Oruka Therapeutics, Inc. ORKA NASDAQ

A biopharmaceutical company developing novel antibody therapies for inflammatory skin diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New drug ORKA-002 tested in humans for the first time Results expected Jan 2027 (estimated)
New psoriasis drug shows promise in Mid-Stage trial Results expected Jun 2027 (estimated) May already have reported ↗

Browse trials soon ready across all sponsors →

Trials to join now! 3 Not yet finished but already full! 3 Completed 1

First human trial for new drug ORKA-001 begins safety check

Knowledge-focused Completed

This early-phase study tested a single injection of ORKA-001 in 24 healthy adults to see if it is safe and how the body processes it. Participants were randomly assigned to receive either the drug or a placebo. The main goal was to check for side effects and changes in vital sign…

Phase 1 • Sponsor: Oruka Therapeutics, Inc. • Aim: Knowledge-focused

Last updated Jun 27, 2026 12:02 UTC

Oruka Therapeutics, Inc.

Upcoming readouts

First human trial for new drug ORKA-001 begins safety check